Standard Document
Third Edition
Microbiology

CLSI M38M51S

Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi

This document provides minimal inhibitory concentration (MIC) breakpoints and quality control (QC) tables for use with CLSI antifungal susceptibility testing standards M38 and M51. It ensures laboratories have the most up-to-date reference data for accurate and standardized susceptibility testing of filamentous fungi and other clinically relevant fungi.

August 04, 2022
Gary W. Procop, MD, MS

{{FormatPrice(currentPrice)}}

Free

{{FormatPrice(nonMemberPrice)}} List Price
This is your member pricing.
Notify Me About New Editions
Abstract

Clinical and Laboratory Standards Institute document M38M51S—Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi includes minimal inhibitory concentration and quality control tables developed following the guidance in CLSI documents M38(1) and M51.(2) The data in the tables are valid only when the methodologies in CLSI documents M38(1) and M51(2) are followed. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition was published appear in boldface type.

Overview of Changes

This document replaces the previous edition of the approved document, M61-Ed2, published in 2020. Several changes were made in this edition, including: (TABLE)

Product Details
M38M51SEd3E
978-1-68440-161-1
36
Authors
Gary W. Procop, MD, MS
Philippe J. Dufresne, PhD, RMCCM
Elizabeth Berkow, PhD
Sharon K. Cullen, BS, RAC
Jeff Fuller, PhD, FCCM, D(ABMM)
Kimberly E. Hanson, MD, MHS
Nicole M. Holliday, BA
Sixto M. Leal, MD, PhD
Audrey N. Schuetz, MD, MPH, D(ABMM)
Paul E. Verweij, MD, FECMM
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)
Abstract

Clinical and Laboratory Standards Institute document M38M51S—Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi includes minimal inhibitory concentration and quality control tables developed following the guidance in CLSI documents M38(1) and M51.(2) The data in the tables are valid only when the methodologies in CLSI documents M38(1) and M51(2) are followed. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition was published appear in boldface type.

Overview of Changes

This document replaces the previous edition of the approved document, M61-Ed2, published in 2020. Several changes were made in this edition, including: (TABLE)

Authors
Gary W. Procop, MD, MS
Philippe J. Dufresne, PhD, RMCCM
Elizabeth Berkow, PhD
Sharon K. Cullen, BS, RAC
Jeff Fuller, PhD, FCCM, D(ABMM)
Kimberly E. Hanson, MD, MHS
Nicole M. Holliday, BA
Sixto M. Leal, MD, PhD
Audrey N. Schuetz, MD, MPH, D(ABMM)
Paul E. Verweij, MD, FECMM
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)